Perjeta (pertuzumab)

Information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor.

Perjeta is a medicine that targets the HER2 receptor, which is designed specifically to prevent the HER2 receptor from pairing with other HER receptors on the surface of cancer cells. Binding of Perjeta to HER2 may also signal the body’s immune system to destroy the cancer cells. The mechanisms of action of Perjeta and Herceptin (trastuzumab) are believed to complement each other and provide a more comprehensive dual blockade of HER signaling pathways, thus preventing tumor cell growth and survival.1

 

In Bangladesh Perjeta is approved for the following indications.2

  • Metastatic Breast Cancer
  • Early Breast Cancer

 

For more disease and medicine related queries you may discuss with your physician.

 

In Bangladesh Perjeta is available as

Vials 420 mg/14 ml

 

References

1. Global Website: Products – Perjeta. [Internet; cited 2018, November 08]. Retrieved from https://www.roche.com/products/product-details.htm?productId=8197b6d7-c981-4418-aafa-e50356ea0f36

2. Perjeta Product Information _ FE-REG-English Ro 436-8451 _ February 2018 – based on CDS 9.0